Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2011; 17(14): 1858-1865
Published online Apr 14, 2011. doi: 10.3748/wjg.v17.i14.1858
Figure 5
Figure 5 Each patient’s (A), total (B), acid reflux (C) and dysmotility (D) FSSG scores in subjects with non-erosive gastroesophageal reflux disease responsive and refractory to the rabeprazole(10*4) regimen. Frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) scores in subjects with non-erosive gastroesophageal reflux disease (NERD) who responded to the RPZ(10*4) regimen improved > 30% compared with baseline with rabeprazole 10 mg od. RPZ: Rabeprazole. aP < 0.05 [vs baseline ]; cP < 0.05 [vs RP (10) ].